Please use this identifier to cite or link to this item:
Title: Distribution of HCV genotypes in Belgium from 2008 to 2015
Authors: Bouacida, Lobna
Suin, Vanessa
Hutse, Veronik
Boudewijns, Michael
Cartuyvels, Reinoud
Debaisieux, Laurent
De Laere, Emmanuel
Hallin, Marie
Hougardy, Nicolas
Lagrou, Katrien
Oris, Els
Padalko, Elizaveta 
Reynders, Marijke
Roussel, Gatien
Senterre, Jean-Marc
Stalpaert, Michel
Ursi, Dominique
Vael, Carl
Vaira, Dolores
Van Acker, Jos
Verstrepen, Walter
Van Gucht, Steven
Kabamba, Benoit
Quoilin, Sophie
Muyldermans, Gaetan
Issue Date: 2018
Source: PLOS ONE, 13(12) (Art N° e0207584)
Abstract: Background The knowledge of circulating HCV genotypes and subtypes in a country is crucial to guide antiviral therapy and to understand local epidemiology. Studies investigating circulating HCV genotypes and their trends have been conducted in Belgium. However they are outdated, lack nationwide representativeness or were not conducted in the general population. Methods In order to determine the distribution of different circulating HCV genotypes in Belgium, we conducted a multicentre study with all the 19 Belgian laboratories performing reimbursed HCV genotyping assays. Available genotype and subtype data were collected for the period from 2008 till 2015. Furthermore, a limited number of other variables were collected: some demographic characteristics from the patients and the laboratory technique used for the determination of the HCV genotype. Results For the study period, 11,033 unique records collected by the participating laboratories were used for further investigation. HCV genotype 1 was the most prevalent (53.6%) genotype in Belgium, with G1a and G1b representing 19.7% and 31.6%, respectively. Genotype 3 was the next most prevalent (22.0%). Further, genotype 4, 2, and 5 were responsible for respectively 16.1%, 6.2%, and 1.9% of HCV infections. Genotype 6 and 7 comprise the remaining <1%. Throughout the years, a stable distribution was observed for most genotypes. Only for genotype 5, a decrease as a function of the year of analysis was observed, with respectively 3.6% for 2008, 2.3% for 2009 and 1.6% for the remaining years. The overall M:F ratio was 1.59 and was mainly driven by the high M:F ratio of 3.03 for patients infected with genotype 3. Patients infected with genotype 3 are also younger (mean age 41.7 years) than patients infected with other genotypes (mean age above 50 years for all genotypes). The patients for whom a genotyping assay was performed in 2008 were younger than those from 2015. Geographical distribution demonstrates that an important number of genotyped HCV patients live outside the Belgian metropolitan cities. Conclusion This national monitoring study allowed a clear and objective view of the circulating HCV genotypes in Belgium and will help health authorities in the establishment of cost effectiveness determinations before implementation of new treatment strategies. This baseline characterization of the circulating genotypes is indispensable for a continuous surveillance, especially for the investigation of the possible impact of migration from endemic regions and prior to the increasing use of highly potent direct-acting antiviral (DAA) agents.
Notes: [Bouacida, Lobna] Sciensano, Lab Med Microbiol, Brussels, Belgium. [Suin, Vanessa; Hutse, Veronik; Van Gucht, Steven] Sciensano, Viral dis, Brussels, Belgium. [Suin, Vanessa; Hutse, Veronik; Van Gucht, Steven; Kabamba, Benoit] Natl Reference Ctr Hepatitis Viruses, Brussels, Belgium. [Boudewijns, Michael] AZ Groeninge, Campus Kennedylaan Lab, Kortrijk, Belgium. [Cartuyvels, Reinoud] Jessa Ziekenhuis, Klin Lab, Hasselt, Belgium. [Debaisieux, Laurent] CUB Hop Erasme, LHUB ULB Site Anderlecht, Brussels, Belgium. [De Laere, Emmanuel] AZ Delta, Roeselare, Belgium. [Hallin, Marie] LHUB ULB, Brussels, Belgium. [Hougardy, Nicolas] Clin Sud Luxembourg, Site St Joseph Labo Anal Med, Arlon, Belgium. [Lagrou, Katrien] UZ Leuven, Clin Dept Lab Med, Leuven, Belgium. [Lagrou, Katrien] Katholieke Univ Leuven, Dept Microbiol & Immunol, Leuven, Belgium. [Oris, Els] Ziekenhuis Oost Limburg, Labo Klin Biol, Genk, Belgium. [Padalko, Elizaveta] UZ Ghent, Clin Biol Med Microbiol Lab, Ghent, Belgium. [Reynders, Marijke] AZ Sint Jan Brugge Oostende AV, Lab Med, Brugge, Belgium. [Roussel, Gatien] Clin St Pierre, Lab Biol Clin, Ottignies, Belgium. [Senterre, Jean-Marc] Ch Reg Citadelle, Liege, Belgium. [Stalpaert, Michel] Algemeen Med Lab, Antwerp, Belgium. [Ursi, Dominique] Univ Hosp Antwerp, Lab Mol Diagnost Microbiol, Antwerp, Belgium. [Vael, Carl] AZ KLINA, Clin Lab, Brasschaat, Belgium. [Vaira, Dolores] CHU Liege, Lab Reference SIDA ULg, Liege, Belgium. [Van Acker, Jos] AZ Sint Lucas, Ghent, Belgium. [Verstrepen, Walter] ZNA, Klin Lab, Campus Middelheim, Antwerp, Belgium. [Kabamba, Benoit] Clin Univ St Luc, Lab Biol Clin Ria, Brussels, Belgium. [Quoilin, Sophie; Muyldermans, Gaetan] Sciensano, Epidemiol Infect Dis, Brussels, Belgium.
Document URI:
ISSN: 1932-6203
e-ISSN: 1932-6203
DOI: 10.1371/journal.pone.0207584
ISI #: 000452212400047
Rights: 2018 Bouacida et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Category: A1
Type: Journal Contribution
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
bouacida 1.pdfPublished version1.88 MBAdobe PDFView/Open
Show full item record

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.